Terminated psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Terminated is a registry status. The study stopped early and will not start again. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 52 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 7 |
| MDMA | 4 |
| LSD | 1 |
| DMT | 1 |
| 5-MeO-DMT | 3 |
| Ketamine | 38 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 2% |
| Phase 1 | 16 | 31% |
| Phase 2 | 22 | 42% |
| Phase 4 | 6 | 12% |
| Not applicable | 4 | 8% |
| Not reported | 3 | 6% |
Countries
Country is taken from the study's linked research site. 0 of 52 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 37 | 71% |
| Canada | 4 | 8% |
| United Kingdom | 2 | 4% |
| Ireland | 2 | 4% |
| Belgium | 1 | 2% |
| Switzerland | 1 | 2% |
| Germany | 1 | 2% |
| Denmark | 1 | 2% |
| Israel | 1 | 2% |
| Netherlands | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 6 |
| 2020 to 2023 | 17 |
| 2015 to 2019 | 11 |
| 2010 to 2014 | 14 |
| Before 2010 | 4 |
Study design
- 49 interventional and 3 observational studies.
- Median planned or actual enrolment is 6 participants (range 1 to 200, across 52 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 23 |
| Suicidal thoughts | 5 |
| Trauma and PTSD | 4 |
| Cancer and end of life | 4 |
| Other substance use | 3 |
| Pain and headache | 3 |
| Obsessive-compulsive disorder | 3 |
| Anxiety | 2 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT06624137 | Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics | Terminated | Not reported | United States | 2024-12 |
| NCT06511947 | Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects | Terminated | Phase 1 | United Kingdom | 2024-08 |
| NCT05910775 | Role Of Non-Specific Effects in The Treatment of Depression With Esketamine | Terminated | Not applicable | United States | 2024-07 |
| NCT06111339 | Ketamine for OUD and Suicidal Ideation in the ED | Terminated | Phase 2 | United States | 2024-06 |
| NCT06431386 | Behavioural Activation Therapy and Esketamine for Resistant Depression | Terminated | Not applicable | Canada | 2024-06 |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Terminated | Phase 4 | United States | 2024-05 |
| NCT05839509 | Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | Terminated | Phase 2 | Germany | 2023-04 |
| NCT05322954 | Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | Terminated | Phase 1 | United States | 2023-03 |
| NCT05804708 | Phase 2 Clinical Trial of GH001 in Postpartum Depression | Terminated | Phase 2 | Netherlands | 2023-03 |
| NCT05522673 | [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine | Terminated | Phase 1 | United States | 2023-02 |
| NCT05323019 | Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression | Terminated | Phase 2 | Canada | 2022-10 |
| NCT04955470 | Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics | Terminated | Phase 1 | Canada | 2022-06 |
| NCT05051449 | Ketamine for OUD and Comorbid Depression (OUDCD) | Terminated | Phase 1 | United States | 2022-04 |
| NCT04613453 | Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine | Terminated | Phase 2 | United States | 2022-01 |
| NCT05193318 | KAP for Depression in Abstinent Opioid Users | Terminated | Phase 2 | United States | 2022-01 |
| NCT05095792 | Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG) | Terminated | Not reported | United States | 2021-11 |
| NCT04784143 | Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | Terminated | Phase 2 | United States | 2021-11 |
| NCT04424225 | Visual Surround Suppression and Perceptual Expectation Under Psilocybin | Terminated | Phase 1 | United States | 2021-08 |
| NCT04905121 | Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) | Terminated | Phase 1 | United Kingdom | 2021-08 |
| NCT04429685 | The Effects of Low Dose Ketamine on Cardiovascular Function | Terminated | Phase 1 | United States | 2020-11 |
| NCT04353921 | PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder | Terminated | Not reported | United States | 2020-06 |
| NCT04280055 | Prophylactic Effects of Psilocybin on Chronic Cluster Headache | Terminated | Phase 1 | Denmark | 2020-01 |
| NCT04082858 | Ketamine Interleaved With Electroconvulsive Therapy for Depression | Terminated | Phase 1 | Ireland | 2020-01 |
| NCT04154150 | Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot | Terminated | Phase 4 | United States | 2019-12 |
| NCT03889756 | Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy | Terminated | Phase 2 | United States | 2019-07 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable